---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-031923"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-07-16T23:59:59+00:00"
generated_at: "2026-05-31T20:29:40.491654+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics appoints Mittie Doyle, M.D., as CMO; grants 234,000-share option

## Summary
- Dr. Doyle, former CMO at Aro Biotherapeutics, brings over 20 years of pharma/biotech experience.
- She will lead Phase 2 LOTUS Trial for AVTX-009 in hidradenitis suppurativa.
- Base salary of $500,000, target bonus of 40%, and inducement stock option for 234,000 shares vesting over 4 years.
- Severance includes nine months' salary (12 months post-change-in-control), full option vesting, and COBRA.
- Appointment effective July 15, 2024; employment agreement filed as Exhibit 10.1.

## SEC filing metadata
- accession: 0001628280-24-031923
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-07-16T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024031923/0001628280-24-031923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024031923/avtx-20240715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-031923
- JSON: https://secwatch.observer/filing/0001628280-24-031923.json
- Plain text: https://secwatch.observer/filing/0001628280-24-031923.txt

## Key facts
- Executive change
  Mittie Doyle was appointed as Chief Medical Officer at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On July 16, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Mittie Doyle, M.D., FACR, as Chief Medical Officer, effective July 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828024031923/0001628280-24-031923-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.